বসনিয়া ও হার্জেগোভিনা - ক্রোয়েশীয় - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pharmacol international d.o.o. - joversol - rastvor za injekciju/ infuziju - 741 mg/1 ml - 1 ml rastvora za injekciju/infuziju sadrži:741 mg joversola, (što odgovara 350 mg joda)

বসনিয়া ও হার্জেগোভিনা - ক্রোয়েশীয় - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pharmacol international d.o.o. - joversol - rastvor za injekciju/ infuziju - 741 mg/1 ml - 1 ml rastvora za injekciju/infuziju sadrži:741 mg joversola, (što odgovara 350 mg joda)

বসনিয়া ও হার্জেগোভিনা - ক্রোয়েশীয় - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pharmacol international d.o.o. - joversol - rastvor za injekciju/ infuziju - 636 mg/1 ml - 1 ml rastvora za injekciju/infuziju sadrži: 636 mg joversola (što odgovara 300 mg joda)

বসনিয়া ও হার্জেগোভিনা - ক্রোয়েশীয় - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pharmacol international d.o.o. - joversol - rastvor za injekciju/ infuziju - 741 mg/1 ml - 1 ml rastvora za injekciju/infuziju sadrži: 741 mg joversola, (što odgovara 350 mg joda)

ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

sonimed d.o.o. rozganska 8 10110 zagreb -

ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - abirateronacetat - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 250 mg abirateronacetata

ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - abirateronacetat - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 500 mg abirateronacetata

ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - abirateronacetat - filmom obložena tableta - urbroj: svaka filmom obložena tableta sadrži 1000 mg abirateronacetata

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

novartis europharm limited - everolimus - carcinoma, renal cell; breast neoplasms; pancreatic neoplasms - antineoplastična sredstva - hormon-receptor pozitivnim čest grudi cancerafinitor indiciran za liječenje hormon-receptor pozitivan, i her2/neu-negativan preliminarnim raka dojke, u kombinaciji s exemestane, u post-menopausal žene bez simptomatske brutalna patologije nakon recidiva ili progresije bolesti nakon non-steroidal i abs битор. Нейроэндокринные tumora gušterače originafinitor indiciran za liječenje operirati ili метастатической, dobro ili umjereno diferencirani нейроэндокринные tumora gušterače podrijetla u odraslih s прогрессирующим bolest. Нейроэндокринные tumora gastrointestinalnog trakta ili pluća originafinitor indiciran za liječenje operirati ili метастатической dobro diferenciranih (klase 1 ili klase 2) нефункционирующие нейроэндокринные tumora gastrointestinalnog ili plućne bolesti podrijetla u odraslih s прогрессирующим bolest. Почечно-stanični carcinomaafinitor indiciran za liječenje bolesnika s prevladava почечно-stanica karcinoma, bolesti koje развивало nakon obrade na vegf-таргетной terapija.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - Ипилимумаб - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastična sredstva - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 i 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.